Health

FDA rejects Summit lung cancer drug after trial fails to show survival benefit

The decision marks a major regulatory hurdle for ivonescimab, a bispecific antibody licensed from China that had generated widespread enthusiasm across the oncology sector.

Ecg, electrocardiogram, stethoscope
Myriams-Fotos / Pixabay, Pixabay Content License

The Food and Drug Administration has declined to approve a closely watched lung cancer medicine developed by Summit Therapeutics, delivering a significant setback to a therapy that had emerged as a benchmark for Chinese drug innovation, The New York Times reported Sunday.

Summit Therapeutics, a biopharmaceutical firm based in Miami, Florida, announced the agency’s decision on Sunday. The company had submitted a biologics license application for ivonescimab, an investigational antibody intended for patients with advanced or metastatic non-small cell lung cancer whose tumors harbor epidermal growth factor receptor mutations.

Missing a Crucial Survival Endpoint

The regulatory rejection was driven by survival outcomes in the drug’s late-stage clinical evaluation. According to The New York Times, Summit stated that the FDA turned down the application because the drug did not achieve a statistically significant improvement in extending overall patient survival during its pivotal global trial.

The application rested on findings from HARMONi, a randomized, double-blind Phase III study that paired ivonescimab with platinum-based chemotherapy against a regimen of chemotherapy and a placebo, according to a corporate release distributed by Yahoo Finance. Patients enrolled in the trial had locally advanced or metastatic non-squamous non-small cell lung cancer that had progressed following treatment with a third-generation EGFR tyrosine kinase inhibitor.

While HARMONi succeeded on its co-primary endpoint of progression-free survival—making it the first global Phase III immunotherapy trial to establish such an advantage in that setting—it fell short of demonstrating a statistically valid extension of overall life expectancy.

Safety data released from the HARMONi trial indicated that the therapy was manageable and consistent with earlier findings, according to the company. Treatment-related adverse events prompted 16 patients, or 7.3 percent, to stop taking ivonescimab, compared to 11 patients, or 5.0 percent, who discontinued in the control group. Four patients, or 1.8 percent, in the ivonescimab arm died from treatment-related adverse events, compared with five patients, or 2.3 percent, in the chemotherapy-alone arm.

Global Origins and Broad Ambitions

Ivonescimab was originally developed by Akeso Biopharma in China, where it secured initial regulatory approval for commercial use in May 2024. Summit subsequently acquired licensing rights to develop and commercialize the drug across North America, South America, Europe and several other international regions.

The drug represents a novel therapeutic class known as a bispecific antibody, designed to simultaneously inhibit programmed cell death protein 1 and vascular endothelial growth factor. By binding to both targets on a single molecule, the treatment aims to unleash an immune response while cutting off blood vessel growth that feeds tumors. Currently, no PD-1 and VEGF bispecific antibodies have received marketing approval in the United States.

Despite the domestic regulatory denial, company leaders signaled that clinical research into the compound will proceed across a range of other tumor types.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Robert W. Duggan, chairman and co-chief executive officer of Summit, said in a statement. “With five positive Phase III studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab’s development.”

What Comes Next for Ivonescimab

Summit continues to evaluate the therapy across extensive clinical programs worldwide. Ongoing Phase III studies include HARMONi-3 and HARMONi-7 in first-line metastatic lung cancer, as well as trials targeting metastatic colorectal cancer and advanced urothelial carcinoma, according to the company.

The drugmaker is also collaborating with major pharmaceutical partners, including AstraZeneca, Daiichi Sankyo, GSK and Revolution Medicines, to test ivonescimab in combinations against breast, gastrointestinal, head and neck, and kidney cancers. Whether Summit will collect additional survival data to revisit its U.S. application for this initial lung cancer indication remains uncertain.